Approach
BroadOak Asset Management was founded to back growth-stage life sciences companies in tools, services, manufacturing, pharma tech and health tech. Many next-generation technologies begin inside these companies, and their founders need a partner who understands both the science and the business. We excel at supporting founders as they navigate the unique complexities and risks of life science commercialization.
We invest in companies that already sell their products or services. Our mandate is broad, so the size and structure of each investment follow the needs of the business.
What We Look For
Sector
Life sciences infrastructure, including tools, services, manufacturing, pharma tech and health tech.
Stage
Commercial, with paying customers and a product or service the market has already validated.
What We Provide
Flexible Structure
Growth equity, structured or convertible debt, or a combination, sized to the opportunity.
Partnership
Industry expertise and a network that add value well beyond the capital itself.
Expertise
Our team combines operating, scientific and investment banking backgrounds, with depth in cell and gene therapy, single-cell analysis, bioprocessing and life sciences software. BroadOak executives serve on the boards of life sciences companies and industry organizations, and that network gives portfolio companies access to customers, acquirers and talent.
The Firm
Bill Snider and Lars Hanan founded BroadOak Capital Partners in 2006 to bring growth capital and advisory services to life sciences companies overlooked by traditional financial institutions. The firm made its first investment in 2010 and today operates from Raleigh and San Francisco through two businesses: BroadOak Asset Management, which invests, and BroadOak Partners, which advises on M&A and financing.
BioTools Innovator
BroadOak has sponsored BioTools Innovator (BTI), the nonprofit accelerator for life science tools and diagnostics companies, since it launched in 2020, and sits on the committee that selects each year’s cohort from several hundred applicants. Companies in the program receive months of mentorship from senior industry leaders, access to investors and a peer network, and compete for an award at the close.
Our partnership with BroadOak extends far beyond a capital investment. Their advice and industry connections have been valuable assets in our growth strategy.
BroadOak knows the life sciences tools and services industry inside and out. From start to finish, our relationship has been a true partnership.
Accellix is benefiting from the BroadOak team’s deep industry expertise, high engagement, and constant availability to advise us on strategic matters. From a transaction perspective, BroadOak has tailored a structure to meet our needs.
The scale and dynamics of our industry sector have changed dramatically since BroadOak’s start 20 years ago. Our clients and partners continue to appreciate the consistency of our core focus and approach.